BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Arana Therapeutics Non-Independent Director Resigns After Takeover Offer


3/2/2009 12:20:04 PM

Monday 2nd March 2009 - Antibody therapeutics company Arana Therapeutics Ltd (ASX: AAH) today announced the resignation of Dr George Jessup as a non-independent director of the company, following the proposed takeover offer from Cephalon Inc. (Nasdaq: CEPH).

As part of its takeover bid, Cephalon has acquired an ownership position in Arana representing approximately 19.9% of Arana’s total issued share capital. This position has been acquired from Arana’s largest two shareholders; Start-up Australia Ventures Pty Ltd (Start-Up) and Rockwell Securities. Start-up is an entity associated with Dr George Jessup. Start-up has sold 19.0 million out of its 22.4 million shares to Cephalon.

Dr Jessup has advised Arana he believed it was an appropriate time for him to step aside.

Arana Chairman, Robin Beaumont said, “We have very much appreciated the contribution made by George and the value he has brought to Arana’s board. George brought a wealth of experience to the Arana Board, with his extensive experience in the Australian biotechnology industry. George has also been an integral part of Arana’s recent development and his contribution to commercialising Arana’s assets has been significant.”

About Arana Therapeutics:

Arana Therapeutics (ASX: AAH) is a biopharmaceutical company focused on developing next generation antibody based drugs that will improve the lives of patients with inflammatory diseases and cancer.

Arana Therapeutics’ innovative engineering technologies provide the basis for developing its next generation antibody candidates. Arana Therapeutics has the financial strength and management expertise to develop its product pipeline. Arana has a significant track record of commercialising its technologies and has collaborations with GlaxoSmithKline (GSK), CSL, Kyowa Hakko Kirin (KHK), and licensing arrangements with Centocor (J&J) and Abbott Laboratories.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES